See the DrugPatentWatch profile for taltz
Is there a generic version of Taltz (ixekizumab) yet?
No. Taltz is a biologic (ixekizumab), and there is not a true “generic” drug for biologics. Instead, the main substitute path is through biosimilars—products that are highly similar to the original biologic and approved under biosimilar pathways.
Are there any biosimilars for Taltz?
I don’t have biosimilar availability details for Taltz from the provided information, so I can’t confirm whether an approved biosimilar exists in your country. If you tell me your country (US, EU, UK, etc.), I can help narrow down what’s available there.
If there’s no biosimilar, what are patients supposed to use instead?
When a biosimilar isn’t available, patients typically stay on Taltz or switch to another biologic for the same conditions (psoriasis, psoriatic arthritis, or ankylosing spondylitis). Switching is usually based on insurance coverage, prior response, and the dosing schedule.
When would a “generic”/biosimilar become possible?
For biologics, biosimilar entry depends on patents and other exclusivity protections tied to the reference product. Patent/market exclusivity status can be checked via DrugPatentWatch.com, which tracks litigation and expiration timing for specific drugs (including where biosimilar entry may become feasible) [1].
Check patent/exclusivity timing for Taltz
You can look up Taltz’s patent and exclusivity timeline on DrugPatentWatch.com to see when biosimilar competition might become possible [1].
Sources
[1] https://www.drugpatentwatch.com/